AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) EVP Sells $302,595.80 in Stock

Key Points

• Amneal Pharmaceuticals EVP Andrew S. Boyer sold 33,436 shares for approximately $302,595.80, reducing his stake by 11.53% to 256,670 shares.
• Amneal's stock price increased by 4.2% to reach $9.40 following the sale, with a market cap of $2.95 billion.
• The company recently posted a quarterly EPS of $0.23, exceeding analysts' expectations, and has a consensus rating of "Buy" with a price target of $11.60.

AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Get Free Report) EVP Andrew S. Boyer sold 33,436 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $302,595.80. Following the transaction, the executive vice president owned 256,670 shares in the company, valued at $2,322,863.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

AMNEAL PHARMACEUTICALS Price Performance

NASDAQ AMRX traded down $0.09 during trading on Monday, hitting $9.37. The company's stock had a trading volume of 234,676 shares, compared to its average volume of 1,686,029. The company has a market cap of $2.94 billion, a PE ratio of 937.44 and a beta of 1.11. The business's 50 day simple moving average is $8.21 and its 200-day simple moving average is $7.97. AMNEAL PHARMACEUTICALS, INC. has a fifty-two week low of $6.68 and a fifty-two week high of $9.59.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. Analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On AMNEAL PHARMACEUTICALS

A number of institutional investors and hedge funds have recently modified their holdings of AMRX. GAMMA Investing LLC lifted its holdings in AMNEAL PHARMACEUTICALS by 5,975.0% in the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after acquiring an additional 3,107 shares during the period. Headlands Technologies LLC acquired a new position in AMNEAL PHARMACEUTICALS in the first quarter valued at approximately $31,000. Amalgamated Bank lifted its holdings in AMNEAL PHARMACEUTICALS by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after acquiring an additional 1,367 shares during the period. GF Fund Management CO. LTD. acquired a new position in AMNEAL PHARMACEUTICALS in the fourth quarter valued at approximately $52,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in AMNEAL PHARMACEUTICALS by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company's stock valued at $98,000 after acquiring an additional 1,735 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on AMRX. Wall Street Zen lowered AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $11.60.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.